The efficacy and safety of IDegLira has been established in the DUAL clinical development program. This post-hoc analysis evaluated glycemic control in the subgroup of patients titrated to the maximum approved IDegLira dose of 50 units (U) (50 U insulin degludec + 1.8 mg liraglutide), from trials that evaluated IDegLira vs. other comparators (DUAL I-V and VII). In all DUAL trials, baseline A1C was similar between IDegLira and comparator arms. In DUAL I-V, regardless of end-of-trial (EOT) doses (50 or <50 U), more patients on IDegLira achieved the American Diabetes Association target of A1C <7% vs. monotherapy of basal insulin, glucagon-like peptide-1 receptor agonist or placebo comparators (Figure). In DUAL VII, compared with basal-bolus insulin therapy (insulin glargine 100 U/mL + insulin aspart ≤4 times daily [mean total daily insulin dose of 84 U at EOT]), the percentage of patients achieving an A1C <7% was greater for patients on <50 U of IDegLira and lower for patients at 50 U of IDegLira at EOT.
For patients at 50 U and <50 U of IDegLira, the mean change in A1C at EOT was numerically greater than or similar to comparators for all trials.
In conclusion, a high proportion of patients receiving the maximum approved dose of IDegLira are able to achieve good glycemic control.
L. Meneghini: Advisory Panel; Self; Novo Nordisk Inc., Sanofi US. Consultant; Self; Sanofi US, Novo Nordisk Inc.. Advisory Panel; Self; Intarcia Therapeutics, Inc.. Other Relationship; Self; American Diabetes Association. S. Linjawi: Advisory Panel; Self; Novo Nordisk A/S, Eli Lilly and Company, Sanofi. Research Support; Self; Novo Nordisk A/S, Boehringer Ingelheim GmbH, AstraZeneca, Eli Lilly and Company, Lexicon Pharmaceuticals, Inc.. Speaker's Bureau; Self; Novo Nordisk A/S, Eli Lilly and Company, Sanofi. P. Serusclat: Board Member; Self; Novo Nordisk A/S, Medtronic, Abbott. Research Support; Self; Novo Nordisk A/S, Eli Lilly and Company, Sanofi. T. Vilsbøll: Advisory Panel; Self; Amgen Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, AstraZeneca, MSD K.K., Sanofi, Novo Nordisk A/S. Consultant; Self; Amgen Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, AstraZeneca, MSD K.K., Sanofi, Novo Nordisk A/S. Speaker's Bureau; Self; Amgen Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, AstraZeneca, MSD K.K., Sanofi, Novo Nordisk A/S. Research Support; Self; Eli Lilly and Company, Novo Nordisk A/S. B.F. Agner: Employee; Self; Novo Nordisk A/S. T. Hansen: Employee; Self; Novo Nordisk A/S. L.A. Leiter: Advisory Panel; Self; AstraZeneca. Research Support; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Research Support; Self; GlaxoSmithKline plc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Research Support; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc.. Research Support; Self; Merck & Co., Inc.. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Sanofi. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Advisory Panel; Self; Servier. Speaker's Bureau; Self; Servier. Research Support; Self; Servier. Advisory Panel; Self; Amgen Inc.. Speaker's Bureau; Self; Amgen Inc.. Research Support; Self; Amgen Inc., Esperion Therapeutics, Kowa Pharmaceuticals America, Inc., The Medicines Company. Advisory Panel; Self; Akcea Therapeutics, Novartis Pharmaceuticals Corporation.
